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Abstract 
Background: In a context of controversy about influenza antiviral treatments, this study 
assessed primary health care physicians’ prescription of neuraminidase inhibitors (NIs) in 
France during pandemic and seasonal influenza between 2009 and 2013.  
Methods: This observational study, using data recorded in three national databases, estimated 
the rate of NIs’ prescription among influenza like-illness (ILI) patients seen in GPs’ and 
paediatricians’ consultations, and determined factors associated with this prescription 
according to a multivariate analysis. NIs’ delivery by pharmacists was also evaluated.  
Results: Rates of NIs’ prescription were estimated to 61.1% among ILI patients with a severe 
influenza risk factor seen in GPs’ consultation during the A(H1N1)pdm2009 pandemic versus 
an average rate of 25.9% during the three following seasonal influenza epidemics. Factors 
associated with NIs’ prescription were a chronic disease in patients under 65 years (OR, 
14.85; 95%CI, 13.00-16.97) and in those aged 65 and older (OR, 7.54; 5.86-9.70), an age ≥ 
65 years in patients without chronic disease (OR, 1.35; 1.04-1.74), a pregnancy (OR, 10.63; 
7.67-15.76), obesity (OR, 4.67; 3.50-6.22), and a consultation during the pandemic 
A(H1N1)pdm2009 (OR, 3.19; 2.93-3.48). The number of antiviral treatments delivered by 
pharmacists during the A(H1N1)pdm2009 pandemic was 835 per 100 000 inhabitants, and an 
average of 275 per 100 000 inhabitants during the three following seasonal influenza 
epidemics.  
Conclusions: Although physicians seem to follow the recommended indications for NIs in 
primary health care practice, this study confirms the low rate of NIs prescription to ILI 
patients with a severe influenza risk factor, especially during seasonal epidemics. 
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Introduction  
Influenza is an acute infectious respiratory disease, which can lead to serious and life-
threatening complications, especially in specific populations such as the elderly and patients 
with a chronic disease. In France, seasonal epidemics are associated with 700,000 to 
4,800,000 consultations for influenza like-illness (ILI) (1-8 % of the general population) [1, 
2], and with 0 to 24 deaths per 100,000 inhabitants [3]. Although vaccination remains the 
most effective prophylactic intervention for influenza infection in the population at risk of 
complications [4, 5],  its effectiveness is estimated only around 60%  in adults between 18 and 
65 years old, and less certain in the other age groups including the elderly [6-8].  
Antiviral treatments thus constitute a complementary prophylactic and therapeutic approach. 
NIs are recommended by French public health authorities [9], as in most other countries [10], 
to treat, as soon as possible, ILI patients i) at risk of influenza complications, defined by 
patients with at least one of the following characteristics: age ≥ 65 years old, chronic 
underlying disease, obesity defined as BMI ≥ 40, or pregnancy; ii) who is hospitalized; iii) or 
has severe, complicated, or progressive illness. Currently only neuraminidase inhibitors (NIs) 
(oseltamivir and zanamivir) may be prescribed, amandatanes are no longer recommended 
because of viral resistance [11]. They reduce the time for alleviation of symptoms in patients 
with a virologically confirmed influenza infection by one day [12, 13, 14, 15]. They decrease 
the occurrence of respiratory complications related to influenza in healthy patients and those 
at risk, the occurrence of pneumonia, and generally the prescription of antibiotics [12, 13, 14-
16]. Finally, they reduce nasal shedding which could limit the spread of the disease [17].  
Despite the results of these studies and the recommendations, the effectiveness of NIs to 
reduce infectivity and transmission, when used as treatment for symptomatic infected 
patients, remains questioned. The latest reviews and meta-analysis challenge the literature 
[13]. They highlight the fact that the populations studied did not specifically include patients 
with a severe influenza risk factor, as the elderly, and that the level of evidence regarding the 
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effect of NIs on mortality and hospitalization was low. There might be a publication bias, 
suggesting that studies showing no impact of antivirals have not been published [12, 15, 18]. 
To better understand how physicians apply recommendations in this debated context, the 
present study was designed to describe NIs’ prescriptions by GPs and paediatricians in France 
during the last pandemic A(H1N1)pdm2009 and the three seasonal epidemics that followed. 
Methods 
In the follow-up to the BIVIR clinical trial [19, 20], an observational study of NIs’ 
prescriptions has been conducted using three French national databases: i) French GPs’ 
Sentinel network database to study NIs’ prescription in ILI patients seen in general 
practitioners (GPs)’ consultations, ii) GROG network database to study NIs’ prescription in 
ILI patients seen in GPs’ and paediatricians’ consultations ≤ 48h after onset of symptoms, iii) 
and IMS Health database to study NIs’ delivery in pharmacies. 
French GPs’ Sentinel network database 
French GPs’ Sentinels network [21], focused on infectious diseases, consists of 1,298 general 
practitioners (GPs), 2.1% of all GPs with a liberal or mixed activity in France. Sentinels GPs’ 
characteristics are comparable to those of all French GPs regarding regional distribution, 
proportion in rural practice, type of practice and distribution of main clinical skills [22]. 
Sentinel physicians transmit every week by Internet the number of patients seen in 
consultation for ILI. ILI was defined as a sudden onset of fever over 39°C with myalgia and 
respiratory symptoms (cough, sore throat). For each case, data collected by GPs were age, 
sex, influenza vaccination for the current season, prescription of antiviral treatment, chronic 
underlying disease without any specification, obesity, pregnancy and if a hospitalisation was 
requested. The date of onset of symptoms was not reported.  
GROG network database 
GROG network [23], focused on influenza and respiratory virus, consists of 526 
representative physicians (391 GPs and 114 paediatricians) distributed over the French 
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territory. Physicians transmit every week by Internet the number of patients seen in 
consultation for ILI, with the same definition as Sentinel physicians. They are asked to 
perform, every week, a clinical questionnaire only for the first ILI case seen in consultation 
≤ 48h after onset of symptom, reporting the same data than Sentinel physicians. 
. 
Inclusion criteria for Sentinel and Grog databases 
All cases reported by Sentinel physicians from July 1, 2009 to June 30, 2013 were included in 
this study, corresponding to four influenza epidemic seasons, 2009/2010, 2010/2011, 
2011/2012, 2012/2013. From January 1, 2009 to June 30, 2013, influenza epidemic periods 
were determined by applying a periodic regression model on weekly ILI incidence rates 
below a cut-off value [1]. All cases reported by Grog physicians during these four epidemics 
periods were included in this study 
Pharmacists’ database 
Private IMS-Pharmastat network consists of 14,000 representative pharmacies distributed 
over the French territory (60% of pharmacies), excluding hospital pharmacies. All medication 
sales are collected weekly. Data are aggregated into therapeutic classes from the Anatomical 
Classification of the European Pharmaceutical Marketing Research Association (EphMRA) 
[24] and an estimation of medication sales in France, out of hospital, is calculated each week. 
From January 1, 2009 to June 30, 2013, sales of influenza antivirals agents (class 
J05B4=oseltamivir and zanamivir), measured in boxes (10 pills per box), were included in the 
study. 
Statistical analysis 
For the two physicians’ databases, a descriptive analysis was performed on all variables 
collected for included cases. A new variable named "Presence of at least one severe influenza 
risk factor" was created, defined by patients with at least one of the following characteristics: 
age ≥ 65 years old, chronic underlying disease, obesity defined as BMI ≥ 40, or pregnancy. 
To prevent a misinterpretation of our results, the rate of NIs’ prescription was analysed for the 
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whole study population, but particularly for cases with the presence of at least one severe 
influenza risk factor. 
Factors associated with NIs’ prescription were studied by performing univariate and then 
multivariate logistic regression. The following explanatory variables were analysed: age, sex, 
influenza vaccination, chronic underlying disease, obesity, pregnancy, pandemic vs. influenza 
season, hospitalisation requested at the end of the consultation, and seen in consultation by a 
GP or a paediatrician. A composite variable was created from “age” and “chronic underlying 
disease” due to a strong interaction (data not shown) between these two variables. From the 
univariate analyses results, a multivariate model was built with all variables with p-values 
<0.20 and then a backward selection approach was used. Analysis were performed in three 
populations: i) all ILI cases, ii) ILI cases seen in consultation ≤48h after onset of symptoms, 
iii) women between 15 and 50 years old. 
Medication sales as influenza antivirals agents were analysed weekly during the study period. 
A reference period of July (year n) to June (year n +1) was chosen to estimate the rate of 
boxes delivered during the influenza epidemic period. 
All analyses were performed with the R software (version 2.13.2; R Development Core Team 
2011).
Results 
Over the four influenza epidemics analysed herein, Sentinel GPs reported 35,188 ILI cases 
distributed in 11,067 ILI cases during the A(H1N1)pdm2009 pandemic, 7,809 during the 
seasonal influenza epidemic in 2010-2011, 4,984 in 2011-2012 and 11,328 in 2012-2013. 
Mean age of patients was 26 years and 48.9% (n=16,923) of them were men. Patients having 
at least one severe influenza risk factor represent 8.9% (n=2,866) of the population. Detailed 
characteristics of cases are given in Table 1. Over the same influenza epidemic periods, 
GROG physicians reported 1,854 ILI cases seen in consultation ≤48h after onset of 
symptoms. Among them, 48.2% (n=894) were included by a GP, and 51.8% (960) by a 
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paediatrician. Mean age was 12 years (22.7 years for GPs’ patients and 2.4 years for 
paediatricians’ patients) and 51.7% (n=950) were men (Table 1). 
NIs’ prescription 
For the whole study period, rate of NIs’ prescription among ILI patients seen in Sentinel GPs’ 
consultation during influenza epidemics was 8.8% (n=2845) (Table 2). The rate of NIs’ 
prescription among ILI patients with at least one severe influenza risk factor was 33.4% 
(n=919) (Table 2); 61.1% during the A(H1N1)pdm2009 pandemic (n=410), 34.5% during the 
seasonal influenza in 2010-2011 (n=176), 23.6% in 2011-2012 (n=146) and 19.6% in 2012-
2013 (n=187). The rate of NIs’ prescription among ILI patients without any severe influenza 
risk factor was 6.4% (n=1863) (Table 2); between 12.3% during the A(H1N1)pdm2009 
pandemic (n=991) and 3.2% in 2012-2013 (n=314). During influenza epidemics, 66.7% of 
NIs’ prescriptions were to patients without any severe influenza risk factor. Oseltamivir 
represented 99.9% of NIs prescription (n=2793), zanamivir 0.1% (n=4).  
Rate of NIs’ prescription among ILI patients seen in GROG GPs’ consultation ≤48h after 
onset of symptom during influenza epidemics was 12.8% (n=114), and 32% (n=32) among 
ILI patients with at least one severe influenza risk factor (Table 2). These data are 
respectively of 11.1% (n=106) and 40% (n=14) among ILI patients seen in GROG 
paediatricians’ consultation ≤48h after onset of symptom.  
During the study period, 6670 ILI cases were declared by Sentinel GPs outside of the 
epidemic periods. Among these cases, 487 (7.5%) had a NIs’ prescription. Patients receiving 
NI outside of the epidemic periods were older (mean age 34.8 vs 29.5, p<0.001) and had more 
frequently obesity (22.6% vs 12.5%, p=0.003) than those during the epidemic periods. There 
was no difference for the other characteristics (sex, seasonal influenza vaccination, presence of at 
least one severe influenza risk factor, chronic underlying disease and pregnancy) (data not shown). 
Factors associated with NIs’ prescription 
In multivariate analysis, factors associated with NIs’ prescription during influenza epidemics 
were a chronic disease in patients under 65 years (OR, 14.85; 95% CI, 13.00-16.97) and in 
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those aged 65 and older (OR, 7.54; 5.86-9.70), an age ≥ 65 years in patients without chronic 
disease (OR, 1.35; 1.04-1.74), obesity (OR, 4.67; 3.50-6.22), and a consultation during the 
pandemic A(H1N1)pdm2009 (OR, 3.19; 2.93-3.48) versus the other three seasons (Table 3). 
Pregnancy was also associated with NIs’ prescription in women population aged between 15 
and 50 years old (OR, 10.63; 7.17-15.76) (Table 4). Among ILI patients seen in consultation 
≤48h after onset of symptoms, same factors were associated with NIs’ prescription (data not 
shown). The medical speciality of the physician (GP or paediatrician) was not associated with 
NIs’ prescription. 
NIs’ delivery by pharmacists 
Between January 2009 and June 2013, the weekly number of NIs boxes delivered in France 
by pharmacists followed strictly the dynamics of influenza epidemics (Figure 1a), and the 
GPs NIs’ prescription (figure 1b). This volume delivered fluctuated according to epidemics 
with a maximum during the pandemic A(H1N1)pdm2009 (n=524,773 or 835.5/100 000 
inhabitants), and a lower level during seasonal epidemics in 2010-2011 (n=181,005 or 
286.6/100 000), 2011-2012 (n=104 624 or 164.7/100 000), and 2012-2013 (n=238,777 or 
373.9/100 000). Zanamivir represented only 157 boxes in 2009-2010, 72 in 2010-2011, 10 in 
2011-2012 and 35 in 2012-2013, other boxes delivered were oseltamivir. 
Over a reference period of July (year n) to June (year n +1), the rate of boxes delivered 
outside the epidemic periods was 4.8% in 2009-2010, 14.3% in 2010-2011, 23.1% in 2011-
2012 and 8.9% in 2012-2013 (Figure 3), corresponding respectively to 26649 NIs’ boxes in 
2009-2010, 30266 in 2010-2011, 31393 in 2011-2012 and 23186 in 2012-2013. Considering a 
margin of 3 weeks before and 3 weeks after the official dates of influenza epidemics, the rate 
of NIs’ prescription outside this “large epidemic period” was 2.4% in 2009-2010, 4.7% in 
2010-2011, 12.4% in 2011-2012 and 3.8% in 2012-2013, corresponding respectively to 
13282, 9869, 16825 and 10040 boxes. 
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Discussion 
In a context of controversy about prescription of influenza antiviral treatments [25, 26], this 
study established in France an inventory of NIs’ prescription and delivery in primary health 
care practice during seasonal epidemics and pandemic between 2009 and 2013.  
As previously reported [27-29], the population which consult a GP or a paediatrician for an 
influenza like-illness, included in our study, was relatively young and healthy. A minority of 
patients included in our study received influenza vaccination. One of the reasons is that 
influenza vaccination, as NIs’ prescription, is recommended in France only for patients at risk 
of severe influenza, who represent a minority of ILI cases seen in GPs consultation during 
influenza epidemics. Our results are consistent with those (5-14.5%) reported in European 
countries [27, 28]. 
Recommendations regarding NIs’ prescription in the treatment of ILI patients at risk of 
influenza complication are consensual, both at the national and international level [9, 10]. 
However, this study showed a low and decreasing NIs’ prescription rate in targeted patients. 
This reluctance of physicians to prescribe NIs to all ILI patients with a severe influenza risk 
factor and follow strictly NIs’ recommendation in primary health care practice has been 
studied recently in United States [30, 31]. In this study, only 195 of 1021 (19%) of ILI 
participants who met high-risk criteria received an antiviral prescription. These low NIs’ 
prescription rates can be explained by different factors. Concerns remain about the NIs’ 
effectiveness, [12, 13, 15, 18], serious side effects are evocated [32], and pharmaceutical 
companies are suspected of a lack of transparency [33, 34]. Moreover, some doubts about 
public influenza expertise have been mentioned with a perception of conflicts of interest 
between experts and pharmaceutical industry [35]. At last, French primary care practitioners 
are very concerned in advices coming from independent educational medical reviews, which 
during the whole study period expressed doubts about oseltamivir effectiveness and interest 
[36]. The gap between the rate of NIs’ prescription among high risk ILI cases seen in 
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consultation by GPs in France during the 2009 pandemic and the following seasonal 
epidemics could reflect the physicians’ perception that seasonal epidemic are less severe, that 
an unknown influenza virus which emerge during a pandemic could have a higher morbidity 
and mortality, and that a NIs’ treatment has to be prescribed more frequently during influenza 
pandemic. 
However, in the present study when NIs were prescribed, there was a good concordance 
between physicians’ practices and the recommendations. A clear association between NIs’ 
prescription and the presence of at least one severe influenza risk factor which reflects the 
recommendation of the public health authorities [9, 10]. The delivery of NIs by pharmacists 
strictly followed the dynamics of influenza epidemics. Respiratory specimens are not 
collected routinely in GPs’ or pediatricians’ offices for influenza testing in France. 
Furthermore, influenza laboratory confirmations were not available for ILI cases included in 
the present study. Although shown in a recent article [30], the association between NIs’ 
prescription and influenza confirmation could not be tested. 
Another important point is that 6.4% of ILI patients without any severe influenza risk factor 
but seeking physician consultation received NIs. It is difficult to know whether these 
prescriptions adhere to the recommendations or not; these latter specify that NIs have to be 
prescribed for ILI patients with severe symptoms or according to the discretion of the 
physician [9, 10]. Regardless, these prescriptions for patients without severe influenza risk 
factors represented a high proportion (66.7%) of all NIs’ prescriptions during influenza 
epidemic periods since 2009, and should be explored. Another intriguing result found in this 
study is the existence of NIs’ prescription outside the epidemic periods. The 
recommendations stipulate that NIs are to be prescribed only during the circulation period of 
influenza virus. French official epidemic periods, used in our study, are defined by a 
statistical method [1], which does not forcibly reflect the circulation of influenza virus. It is 
possible that the perception of the influenza epidemic periods was quite different for the 
physicians. However, even if we take a margin of 3 weeks before and 3 weeks after the 
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official dates, NIs’ prescriptions outside this “large epidemic period” were still found. These 
results are difficult to explain, and the reasons for such prescription should be explored in 
subsequent studies. 
We must recognize several limitations to this study. The fact that we use pre-existent 
physicians’ database did not permit the collection of more precise biomedical, psychosocial 
and socio-demographic data about ILI patients, which could be associated to NIs’ 
prescription. In the same way, we did not have data about physicians’ characteristics. As 
expected [29], the rate of hospitalizations requested by GPs among ILI cases seen in primary 
health care consultations was low. The fact that it is an infrequent event could explain the lack 
of power to show an association between hospitalization and NIs’ prescription, although it is a 
specific factor in the French NIs’ recommendations. Pharmacist’s database was limited to the 
number of boxes delivery without any clinical or social information about patients who 
received NIs. Conversely this study presented the advantage of the large number of subjects 
included in the physicians’ databases. Inclusion of the whole ILI patients seen in Sentinel 
GPs’ consultations during the epidemic period avoided a risk of a selection bias. The use of 
two different and complementary physicians’ databases, showing close results, reinforces our 
conclusions. Another advantage of the study’s design is the use of physicians’ and 
pharmacists’ databases, which permit to present data about prescription and delivery. 
Although physicians seem to follow recommended indications for NIs’ antiviral use in 
primary health care practice, this study confirms their hesitation to prescribe NIs to all ILI 
patients with a severe influenza risk factor. It would be useful to try to understand the reasons 
of the gap between experts’ recommendations and physicians’ practices. A prospective study 
would better assess biomedical, psychosocial and socio-demographic factors associated with 
NIs’ prescription. Considering this reluctance from GPs to prescribe NI systematically to ILI 
patients with a severe influenza risk factor, it could be interesting to modulate our public 
health messages. Improvement of adherence to NIs’ prescription might be focused among 
those for whom influenza vaccination is less effective. For example, when the early estimate 
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suggests that the influenza vaccine has low effectiveness against circulating influenza, as 
against the (H3N2) viruses circulating this year [37]. 
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Table 1: Description of ILI cases included between 2009 and 2013, 35188 cases seen in GPs’ 
consultation (French GPs’ Sentinels database) and 1854 seen in GPs’ and paediatricians’ 
consultation ≤48h after onset of symptoms (GROG network database) 
 French GPs’ 
Sentinels database 
GROG network  
database 
 
Included by GPs 
N=35188 
Included by GPs 
N=894 
Included by 
Paediatricians 
N=960 
Age, Median [Quartile] 21 [9 ; 40] 15 [6 ; 37] 2 [1 ; 3] 
< 15 yo, n (%)
 
14003 (39.8) 438 (49.0) 960 (100) 
Male, n (%) 16923 (48.9) 451 (50.7) 499 (52.6) 
Seasonal influenza vaccinated, n 
(%) 
1413 (4.1) 49 (5.5) 16 (1.7) 
Presence of at least one severe 
influenza risk factor*, n (%) 
2866 (8.9) 101 (13.7) 35 (4.3) 
≥ 65 yo, n (%) 1413 (4.0) 34 (3.8) 0 
Chronic underlying disease, 
n (%) 
1487 (4.2) 75 (8.4) 35 (3.6) 
Obesity, n (%) 309 (0.9) 7 (0.8) 0 
Pregnancy, n (%) 121 (0.3) 2 (0.2) 0 
* Presence of a severe influenza risk factor was defined by patients with at least one of the following 
characteristics: age ≥ 65 years old, chronic underlying disease, obesity defined as BMI ≥ 40, and pregnancy 
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Table 2: NIs’ prescription among ILI cases included between 2009 and 2013, 35188 cases 
seen in GPs’ consultation (French GPs’ Sentinels database) and 1854 seen in GPs’ and 
paediatricians’ consultation ≤48h after onset of symptoms (GROG network database) 
 
 2009/2010 2010/2011 2011/2012 2012/2013 Total 
Sentinelles GPs’ 
database * 
N=35188 
NIs’ prescription, n (%) 1440 (16.1) 493 (6.5) 402 (8.2) 510 (4.6) 2845 (8.8) 
among ILI patients with 
at least one influenza 
risk factor***, n (%) 
410 (61.1) 176 (34.5) 146 (23.6) 187 (19.6) 919 (33.4) 
among ILI patients 
without any influenza 
risk factor***, n (%) 
991 (12.3) 309 (4.4) 249 (5.9) 314 (3.2) 1863 (6.4) 
       
Grog GPs 
database ** 
N=894 
NIs’ prescription, n (%) 61 (16.8) 15 (8.3) 14 (11.5) 24 (10.7) 114 (12.8) 
among ILI patients with 
at least one influenza 
risk factor***, n (%) 
17 (43.6) 3 (21.4) 6 (26.1) 6 (25) 32 (32) 
among ILI patients 
without any influenza 
risk factor***, n (%) 
27 (15.3) 11 (6.6) 8 (8.1) 18 (9.3) 64 (10.1) 
       
Grog 
paediatricians’ 
database ** 
N=960 
NIs’ prescription, n (%) 57 (15.7) 18 (9.2) 16 (9.8) 15 (6.4) 106 (11.1) 
among ILI patients with 
at least one influenza 
risk factor***, n (%) 
9 (50) 5 (55.6) 0 (0) 0 (0) 14 (40) 
among ILI patients 
without any influenza 
risk factor***, n (%) 
35 (17.2) 13 (7.0) 16 (10.1) 14 (6.2) 78 (10.1) 
* All ILI cases seen in consultation 
** ILI cases seen in consultation ≤ 48h after onset of symptoms 
*** Presence of a severe influenza risk factor was defined by patients with at least one of the following 
characteristics: age ≥ 65 years old, chronic underlying disease, obesity defined as BMI ≥ 40, and pregnancy 
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Table 3: Factors associated with NIs’ prescription during influenza epidemics since 2009 among 32,458 ILI patients seen in GPs’ consultation 
(univariate and multivariate analysis)  
 Univariate analysis 
 
Multivariate analysis 
N=  31,154 
Variable 
N 
Treated with NIs 
n (%) 
OR OR (IC 95%) p OR OR (IC 95 %) P 
Male 15,657 1,419 (9.1) 1.08 [1.01 ; 1.17] 0.047 -   
Female 16,289 1,374 (8.4) 
   
   
Age ≥65 yo with chronic underlying disease 327 105 (32.1) 6.46 [5.10 ; 8.18] <0.001 7.54 [5.86 ; 9.70] <0.001 
Age ≥65 yo without chronic underlying disease 986 70 (7.1) 1.04 [0.81 ; 1.34] 0.737 1.35 [1.04 ; 1.74] 0.023 
Age <65 yo with chronic underlying disease 1,134 607 (53.5) 15.72 [13.87 ; 17.82] <0.001 14.85 [13.00 ; 16.97] <0.001 
Age <65 yo without chronic underlying disease 29,640 2,023 (6.8)       
Seasonal influenza vaccinated 1,363 262 (19.2) 2.64 [2.29 ; 3.04] <0.001 -   
Not seasonal influenza vaccinated 30,620 2,533 (8.3)       
Obesity
 
303 126 (41.6) 7.73 [6.13 ; 9.75] <0.001 4.67 [3.50 ; 6.22] <0.001 
No obesity 31,793 2,681 (8.4)       
Hospitalisation requested 131 17 (13.0) 1.55 [0.93 ; 2.58] 0.094 -   
No hospitalisation requested 31,352 2,757 (8.8)       
Pandemic A(N1N1)2009 8,918 1,440 (16.1) 3.03 [2.81 ; 3.28] <0.001 3.19 [2.93 ; 3.48] <0.001 
Seasonal influenza epidemic 23,540 1,405 (6.0)       
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Table 4: Factors associated with the NIs’ prescription during influenza epidemics since 2009 among 8008 women aged between 15 and 50 yo 
seen in GPs’ consultation for ILI (univariate and multivariate analysis) 
 Univariate analysis 
 
Multivariate analysis 
N= 7 200 
Variable 
N 
Treated with NIs 
n (%) 
OR OR (IC 95%) p OR OR (IC 95 %) P 
Pregnant 116 53 (45.7) 8.53 [5.87 ; 12.40] <0.001 10.63 [7.17 ; 15.76] <0.001 
Not pregnant 7084 636 (9.0)       
Seasonal influenza vaccinated 169 42 (24.9) 3.27 [2.28 ; 4.70] <0.001 -   
Not seasonal influenza vaccinated 6977 641 (9.2)       
Chronic underlying disease 244 133 (54.5) 13.79 [10.57 ; 18.00] <0.001 12.86 [9.70 ; 17.05] <0.001 
No chronic underlying disease 6956 556 (8.0)       
Obesity
 
91 39 (42.9) 7.45 [4.88 ; 11.38] <0.001 6.56 [4.02 ; 10.68] <0.001 
No obesity 7109 650 (9.1)       
Hospitalisation requested 23 4 (17.4) 1.95 [0.66 ; 5.75] 0.225 -   
No hospitalisation requested 7023 684 (9.7)       
Pandemic A(N1N1)2009 1877 339 (18.1) 3.09 [2.64 ; 3.63] <0.001 3.05 [2.57 ; 3.62] <0.001 
Seasonal influenza epidemic 5395 357(6.6)       
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Figure 1a: Number of boxes of oseltamivir delivered per 100 000 inhabitants per week in France 
between 2009 and 2013, weekly incidence of ILI cases seen in general practice. 
 
* Shaded periods represent influenza epidemic periods determined by applying a periodic regression model on 
weekly ILI incidence rates below a cut-off value [1] 
 
Figure 1b: Number of cases included in the study who received a NIs’ prescription in and outside of 
the influenza epidemic periods in the Sentinel GPs database.  
 
* Shaded periods represent influenza epidemic periods determined by applying a periodic regression model on 
weekly ILI incidence rates below a cut-off value [1] 
 
 
